Respiri Limited (ASX: $RSH) has reported its consolidated financial statements for the half year ended 31 December 2023. The company's principal activities during this period included the research, development, and commercialization of medical devices, along with the development of mobile health applications. Respiri's continued expansion and growth in the US market have been highlighted, particularly following the acquisition of Access Telehealth in August 2023.
Following the acquisition of Access Telehealth, Respiri has focused on integrating and streamlining platforms to enhance the efficient and scalable Remotli platform. The company has also emphasized existing customer growth, finalizing new customer acquisition, and building a supporting organizational structure for its Remote Patient Monitoring (RPM) programs. Respiri's emphasis on these areas is expected to drive revenue growth during the half year. Additionally, the company undertook a $6.5 million placement at $0.03 per share to support its US operations and execute its commercialization strategy, with the aim of achieving cashflow breakeven by the second half of calendar year 2024.
Respiri's half year report reflects its strategic focus on the US market, particularly through the acquisition of Access Telehealth, which has enabled the company to offer a full suite of Remote Patient Monitoring solutions. The company's efforts in existing customer growth, new customer acquisition, and building an organizational structure for RPM programs are expected to drive revenue growth. Furthermore, Respiri's financial highlights include a successful $6.5 million placement to support its US operations and a binding commitment facility for an additional A$20M to fund potential acquisitions in the US. The company's outlook indicates a focus on revenue growth, with plans to continue business development activities and launch new customer programs in Q3 FY24.